Early, goal-directed therapy for septic shock - A patient-level meta-analysis

New England Journal of Medicine

Volumn 376, Issue 23, 2017, Pages 2223-2234

  Rowan, Kathryn M ^a   Angus, Derek C ^a   Bailey, Michael ^a   Barnato, Amber E ^a   Bellomo, Rinaldo ^a   Canter, Ruth R ^a   Coats, Timothy J ^a   Delaney, Anthony ^a   Gimbel, Elizabeth ^a   Grieve, Richard D ^a   Harrison, David A ^a   Higgins, Alisa M ^a   Howe, Belinda ^a   Huang, David T ^a   Kellum, John A ^a   Mouncey, Paul R ^a   Music, Edvin ^a   Peake, Sandra L ^a   Pike, Francis ^a   Reade, Michael C ^a   Sadique, M Zia ^a   Singer, Mervyn ^a   Yealy, Donald M ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE FACTOR; LACTIC ACID; CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG USE; EARLY GOAL DIRECTED THERAPY; HEALTH CARE DELIVERY; HOSPITALIZATION COST; HUMAN; HYPERLACTATEMIA; HYPOTENSION; INTENSIVE CARE; LACTATE BLOOD LEVEL; MEDICAL PROCEDURES; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PATIENT CARE; PRESSOR RESPONSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESUSCITATION; RISK FACTOR; SEPTIC SHOCK; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; AGED; COST BENEFIT ANALYSIS; ECONOMICS; ERYTHROCYTE TRANSFUSION; FEMALE; FLUID THERAPY; HOSPITAL MORTALITY; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHOCK, SEPTIC; SURVIVAL ANALYSIS;

AGED; CARDIOTONIC AGENTS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; FLUID THERAPY; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESUSCITATION; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 85020281572     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1701380     Document Type: Article

References (20)

1. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
2. Nguyen HB, Jaehne AK, Jayaprakash N, et al. Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE. Crit Care 2016;20:160.
3. The ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-93.
4. The ARISE Investigators and the ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014;371:1496-506.
5. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301-11.
6. Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 2015;41:1549-60.
7. Reade MC, Delaney A, Bailey MJ, et al. Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Med 2010;36:11-21.
8. The ProCESS/ARISE/ProMISe Methodology Writing Committee. Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe. Intensive Care Med 2013;39:1760-75.
9. Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005;14:185-96.
10. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96.
11. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461-75.
12. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
13. De Backer D, Vincent JL. Early goaldirected therapy: do we have a definitive answer? Intensive Care Med 2016;42:1048-50.
14. Puskarich MA, Marchick MR, Kline JA, Steuerwald MT, Jones AE. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit Care 2009;13:R167.
15. Sivayoham N, Rhodes A, Jaiganesh T, Van Zyl Smit N, Elkhodhair S, Krishnanandan S. Outcomes from implementing early goal-directed therapy for severe sepsis and septic shock: a 4-year observational cohort study. Eur J Emerg Med 2012;19:235-40.
16. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
17. Shankar-Hari M, Harrison DA, Rowan KM. Differences in impact of definitional elements on mortality precludes international comparisons of sepsis epidemiology - a cohort study illustrating the need for standardized reporting. Crit Care Med 2016;44:2223-30.
18. Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259-71.
19. Vincent JL. Individual gene expression and personalised medicine in sepsis. Lancet Respir Med 2016;4:242-3.
20. Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 2015;191:309-15.